Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of VY-AADC02 in Advanced Parkinson's Disease with Motor Fluctuations
2017-004685-10Phase 2Terminated
- Sponsor
- Voyager Therapeutics
- Start
- Sep 2018
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing VY-AADC02 gene therapy with Placebo surgery (2 arms). Primary endpoint: Change in patient-rated motor fluctuations. Started Sep 2018; status: terminated.
02
Drugs
ezaladcigene resoparvovec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-004685-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004685-10.